Autobio Diagnostics Co Ltd (SHG:603658) — Market Cap & Net Worth
Market Cap & Net Worth: Autobio Diagnostics Co Ltd (603658)
Autobio Diagnostics Co Ltd (SHG:603658) has a market capitalization of $2.55 Billion (CN¥17.42 Billion) as of June 22, 2026. Listed on the SHG stock exchange, this China-based company holds position #5537 globally and #1095 in its home market, demonstrating a 0.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Autobio Diagnostics Co Ltd's stock price CN¥30.49 by its total outstanding shares 571424768 (571.42 Million). Review 603658 current and long-term liabilities to assess the company's total debt and financial obligations.
Autobio Diagnostics Co Ltd Market Cap History: 2016 to 2026
Autobio Diagnostics Co Ltd's market capitalization history from 2016 to 2026. Data shows change from $3.27 Billion to $2.55 Billion (-0.62% CAGR).
Autobio Diagnostics Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Autobio Diagnostics Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.82x
Autobio Diagnostics Co Ltd's market cap is 0.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.06x
Autobio Diagnostics Co Ltd's market cap is 3.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.27 Billion | $980.22 Million | $349.76 Million | 3.33x | 9.34x |
| 2017 | $3.20 Billion | $1.40 Billion | $446.56 Million | 2.28x | 7.16x |
| 2018 | $2.97 Billion | $1.93 Billion | $562.57 Million | 1.54x | 5.28x |
| 2019 | $5.92 Billion | $2.68 Billion | $774.16 Million | 2.21x | 7.65x |
| 2020 | $8.97 Billion | $2.98 Billion | $747.79 Million | 3.01x | 12.00x |
| 2021 | $4.47 Billion | $3.77 Billion | $973.66 Million | 1.19x | 4.59x |
| 2022 | $5.10 Billion | $4.44 Billion | $1.17 Billion | 1.15x | 4.36x |
| 2023 | $4.77 Billion | $4.44 Billion | $1.22 Billion | 1.07x | 3.92x |
| 2024 | $3.65 Billion | $4.47 Billion | $1.19 Billion | 0.82x | 3.06x |
Competitor Companies of 603658 by Market Capitalization
Companies near Autobio Diagnostics Co Ltd in the global market cap rankings as of June 22, 2026.
Key companies related to Autobio Diagnostics Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #147 globally with a market cap of $153.73 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #207 globally with a market cap of $117.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #234 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #247 globally with a market cap of $101.86 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #147 | Abbott Laboratories | NYSE:ABT | $153.73 Billion | $88.41 |
| #207 | Stryker Corporation | NYSE:SYK | $117.79 Billion | $307.80 |
| #234 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #247 | Medtronic PLC | NYSE:MDT | $101.86 Billion | $79.34 |
Autobio Diagnostics Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Autobio Diagnostics Co Ltd's market cap moved from $3.27 Billion to $ 2.55 Billion, with a yearly change of -0.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.55 Billion | -13.92% |
| 2025 | CN¥2.96 Billion | -18.84% |
| 2024 | CN¥3.65 Billion | -23.45% |
| 2023 | CN¥4.77 Billion | -6.45% |
| 2022 | CN¥5.10 Billion | +14.10% |
| 2021 | CN¥4.47 Billion | -50.24% |
| 2020 | CN¥8.97 Billion | +51.48% |
| 2019 | CN¥5.92 Billion | +99.58% |
| 2018 | CN¥2.97 Billion | -7.17% |
| 2017 | CN¥3.20 Billion | -2.10% |
| 2016 | CN¥3.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Autobio Diagnostics Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.55 Billion USD |
| MoneyControl | $2.55 Billion USD |
| MarketWatch | $2.55 Billion USD |
| marketcap.company | $2.55 Billion USD |
| Reuters | $2.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Autobio Diagnostics Co Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immun… Read more